Acceleron names new chair of board
This article was originally published in Scrip
Acceleron Pharma, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutic candidates that regulate cellular growth and repair, has appointed Dr Francois Nader chair of its board of directors. Dr Nader joined the Acceleron board in December 2014. Most recently he was president, CEO and director of NPS Pharma through the recent acquisition of NPS by Shire.
You may also be interested in...
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.